Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Biropepimut-S (Primary) ; Lenalidomide; Poly ICLC
- Indications Myeloma
- Focus Therapeutic Use
- 18 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 18 Dec 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018.
- 01 May 2017 Planned End Date changed from 1 Nov 2013 to 1 Dec 2017.